Although both studies performed CRISPR screen in non-PCa cancer cell lines, they demonstrated that loss of RNASEHEB, which is particularly frequent (up to 20% or more) in the PCa cohort, leads to synthetic lethality by PARP or ATR inhibition, indicating that RNASEH2B status is a potential determinant for treatment with both drugs in PCa patients. The gene discussed is ATR; the disease is posterior cortical atrophy.